Exudative Age-related Macular Degeneration Clinical Trial
RBM-007 is considered a potential new treatment for wet AMD patients with no prior treatment history!
We would like to introduce the clinical trials conducted by our company. As a clinical trial targeting exudative age-related macular degeneration (wet AMD), a Phase 2 clinical trial was conducted in the United States after the implementation of a Phase 1/2a clinical trial, aimed at confirming the clinical proof of concept (POC) of multiple administrations of RBM-007. Furthermore, a physician-led clinical trial was conducted in the United States to evaluate the efficacy and safety of RBM-007 monotherapy in treatment-naive wet AMD patients. 【Main Trials】 ■ Randomized double-blind trial ■ Open-label trial ■ Physician-led clinical trial *For more details, please refer to the PDF materials or feel free to contact us.
- Company：リボミック
- Price：Other
